#mn166

Visit Now - https://zeroviral.com/brief-medicinova-announces-phase-2b-trial-results-in-mn-166-ibudilast/

BRIEF-Medicinova Announces Phase 2B Trial results in MN-166 (Ibudilast)

Feb 1 (Reuters) – Medicinova Inc:

* MEDICINOVA ANNOUNCES MN-166 (IBUDILAST) DEMONSTRATED A 26 PCT REDUCTION IN CONFIRMED DISABILITY PROGRESSION IN THE SPRINT-MS PHASE 2B TRIAL IN PROGRESSIVE MS: POTENTIAL BEST-IN-DISEASE DRUG Source text for Eikon: Further company coverage: